Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials.

Front Oncol · 2020 · PMC7732617 · PMID 33330082

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

nearly significantp = 0.07so close (0.05 < p ≤ 0.1)

There was also a significant improvement of PFS (median: 2.1 months with regorafenib versus 1.1 months with placebo) (adjusted HR = 0.33; 95% CI: 0.15–0.74; p = 0.007) and a large and nearly significant OS benefit despite the cross-over (adjusted HR = 0.49; 95% CI: 0.23–1.06; p = 0.07; median OS = 17.8 versus 8.2 months) ( 47 ) ( Table 3 ).

also in 3,287 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.